The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

MRNA

Concerning the House

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

United States · www.modernatx.com

The Long Run

FY 2018–2025 · 8 years

LineLatestCAGRTrend
Revenue$1.94B+51.0%
Operating income-$3.07B+41.1%
Net income-$3.56B
Cash from ops-$3.12B+193.9%
Quotation

$63.65

-0.02 (-0.0%)

52w hi$81.80
52w lo$22.36
Vol8.16M
As ofAug 13
The Verdict

Hold

Our score -0.34

Short-0.53
Medium-0.02
Long-0.59

computed 2026-08-13

By the Numbers

Moderna, Inc.

Healthcare · Biotechnology

Market cap$25.41B
Enterprise value$21.57B
Trailing P/E
Forward P/E-13.17x
EV / EBITDA-9.83x
P / S (ttm)11.41x
Profit margin-141.4%
Return on equity-39.0%
Revenue growth+2.1%
Earnings growth
Debt / equity19.04
Risk Metrics
Beta vs SPX1.40
Corr SPX0.34
Annual vol67.9%
Annual ret+8.8%
Sharpe0.13
Max DD-75.1%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental-0.22
Sector+0.14
Technical+0.10
Earnings+0.00
Sentiment-0.80

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$63.80$65.33$62.33$63.658.16M
Aug 12$60.58$64.26$59.29$63.676.58M
Aug 11$60.21$61.40$58.60$60.576.56M
Aug 10$59.75$60.77$58.41$59.816.22M
Aug 7$54.79$59.42$54.62$59.176.82M